Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly is doubling down on manufacturing investments announcing a US3 billion expansion of its Wisconsin facility ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Eli Lilly is doubling down on manufacturing investments, announcing a US$3 billion expansion of its Wisconsin facility ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...